EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

Malak Munir iD, Ahmed Sayed, Dae Hyun Lee iD, Sanam Ghazi iD, Mustafa M Houmsse iD, Saad Badat iD, Abdul Moeed, Avirup Guha iD, Daniel Addison, Narendranath Epperla iD

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Malak Munir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rochester General Hospital, Rochester, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Hematologic Neoplasms, Cardiovascular Diseases, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug ( n = 7647) were compared with all other drugs in the database ( N = 7 289 316) and appropriate active comparators. Adjusted reporting odds ratios (aRORs) were estimated using multivariable logistic regression, adjusting for age, sex, cardiovascular comorbidity, disease, and concomitant cardiotoxic medications. Among 7647 BsAb‐associated reports (median age: 60 [36–71] years; 44.6% female), 1408 (18.4%) involved a CVAE and 447 (5.8%) were fatal. BsAbs showed increased reporting of DIC (aROR: 4.35 [3.18–5.96]; n = 49), hypotension (1.61 [1.38–1.89]; n = 181), and fatal CVAEs (1.63 [1.47–1.80]; n = 447). MM‐directed BsAbs were associated with shock (2.09 [1.65–2.66]) and myocarditis (3.68 [1.49–9.10]). Blinatumomab was associated with DIC (4.41 [3.05–6.37]) and hypotension (1.46 [1.18–1.81]). Teclistamab showed the strongest myocarditis signal (5.95 [2.16–16.43]; n = 4). Mosunetuzumab showed increased reporting of atrial fibrillation (2.25 [1.15–4.38]) and supraventricular tachycardia (2.21 [1.17–4.15]). CVAEs occurred earlier than non‐CVAEs (median 7 vs. 15 days; p < 0.001). The majority of hypotension (56.4%) and heart failure (44.2%) reports occurred independently of both CRS and infection. Case fatality proportions for shock (60.1%), DIC (51.0%), and heart failure (48.1%) exceeded those for CRS (24.3%). BsAb‐associated cardiovascular signals, particularly DIC, hemodynamic events, and fatal CVAEs, varied by agent and target antigen. These findings support the need for cardiovascular‐specific monitoring during therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificHematologic NeoplasmsCardiovascular DiseasesAntineoplastic Agents, ImmunologicalHumansFemalePharmacovigilanceMaleMiddle AgedAgedAdultCardiotoxicity

Stichwörter der Autor:innen

FAERSbispecific antibodiescardiovascular toxicitycytokine release syndromehematologic malignanciespharmacovigilance

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medicine, Rochester General Hospital, Rochester, New York, USA.
  • Division of Cardiovascular Medicine, Thalheimer Center for Cardio-Oncology, University of Pennsylvania Medicine, Philadelphia, Pennsylvania, USA.
  • Cardio-Oncology Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Malak Munir, Dae Hyun Lee, Sanam Ghazi, Mustafa M Houmsse, Saad Badat, Avirup Guha, Narendranath Epperla

Zitieren

APA

Munir, M., Sayed, A., Lee, D. H., Ghazi, S., Houmsse, M. M., Badat, S., Moeed, A., Guha, A., Addison, D., & Epperla, N. (2026). Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis. American Journal of Hematology. https://doi.org/10.1002/ajh.70449

Vancouver

Munir M, Sayed A, Lee DH, Ghazi S, Houmsse MM, Badat S, et al. Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis. American Journal of Hematology. 2026. doi:10.1002/ajh.70449

BibTeX
@article{Munir2026,
  author = {Munir, Malak and Sayed, Ahmed and Lee, Dae Hyun and Ghazi, Sanam and Houmsse, Mustafa M and Badat, Saad and Moeed, Abdul and Guha, Avirup and Addison, Daniel and Epperla, Narendranath},
  title = {Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70449}
}
Kostenlos starten →